ERBB2 and non-small cell lung carcinoma: Currently, the most promising HER2-targeted therapy for NSCLC is T-Dxd, with an ORR of 55% in pretreated patients and a median OS of 17.8 months in the phase II Destiny-Lung01 trial [21].